Search Page

1

Cite

Share

Tyrosine kinase inhibitors.

Natoli C, Perrucci B, Perrotti F, Falchi L, Iacobelli S; Consorzio Interuniversitario Nazionale per Bio-Oncologia (CINBO). Natoli C, et al. Among authors: falchi l. Curr Cancer Drug Targets. 2010 Aug;10(5):462-83. doi: 10.2174/156800910791517208. Curr Cancer Drug Targets. 2010. PMID: 20384577 Review.

Cite

Share

2

Cite

Share

The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.

Falchi L, Verstovsek S, Ravandi-Kashani F, Kantarjian HM. Falchi L, et al. Cancer. 2016 Apr 15;122(8):1160-8. doi: 10.1002/cncr.29852. Epub 2015 Dec 30. Cancer. 2016. PMID: 26716387 Free PMC article. Review.

Cite

Share

3

Cite

Share

Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution.

Falchi L, Rege-Cambrin G, Fava C, Donti E, Luzi D, Giugliano E, Gubbiotti M, Schippa M, Liberati AM. Falchi L, et al. Cancer Genet Cytogenet. 2010 Jun;199(2):139-42. doi: 10.1016/j.cancergencyto.2010.02.008. Cancer Genet Cytogenet. 2010. PMID: 20471518

Cite

Share

4

Cite

Share

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.

Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Falchi L, et al. Am J Hematol. 2013 Dec;88(12):1024-9. doi: 10.1002/ajh.23560. Epub 2013 Sep 12. Am J Hematol. 2013. PMID: 23913852 Free PMC article.

Cite

Share

5

Cite

Share

Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.

Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Vitale C, et al. Among authors: falchi l. J Geriatr Oncol. 2020 Jan;11(1):19-23. doi: 10.1016/j.jgo.2019.04.002. Epub 2019 Apr 18. J Geriatr Oncol. 2020. PMID: 31005650

Cite

Share

6

Cite

Share

Kit Mutations: New Insights and Diagnostic Value.

Falchi L, Verstovsek S. Falchi L, et al. Immunol Allergy Clin North Am. 2018 Aug;38(3):411-428. doi: 10.1016/j.iac.2018.04.005. Epub 2018 Jun 9. Immunol Allergy Clin North Am. 2018. PMID: 30007460 Review.

Cite

Share

7

Cite

Share

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

Falchi L, Bose P, Newberry KJ, Verstovsek S. Falchi L, et al. Br J Haematol. 2017 Feb;176(3):352-364. doi: 10.1111/bjh.14443. Epub 2016 Dec 16. Br J Haematol. 2017. PMID: 27984634 Review.

Cite

Share

8

Cite

Share

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia.

Falchi L, Baron JM, Orlikowski CA, Ferrajoli A. Falchi L, et al. Mediterr J Hematol Infect Dis. 2016 Feb 10;8(1):e2016011. doi: 10.4084/MJHID.2016.011. eCollection 2016. Mediterr J Hematol Infect Dis. 2016. PMID: 26977270 Free PMC article. Review.

Cite

Share

9

Cite

Share

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.

Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. Vitale C, et al. Among authors: falchi l. Clin Cancer Res. 2016 May 15;22(10):2359-67. doi: 10.1158/1078-0432.CCR-15-2476. Epub 2016 Jan 5. Clin Cancer Res. 2016. PMID: 26733610 Free PMC article. Clinical Trial.

Cite

Share

10

Cite

Share

New Therapeutic Approaches in Polycythemia Vera.

Falchi L, Newberry KJ, Verstovsek S. Falchi L, et al. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl(0):S27-33. doi: 10.1016/j.clml.2015.02.013. Clin Lymphoma Myeloma Leuk. 2015. PMID: 26297275 Free PMC article. Review.

Cite

Share